Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$46.16M, compared with -$57.37M a year earlier. Trailing-twelve-month operating income was -$191.86M.
Context
- Operating income amounted to 566038.9% of revenue in FY2025, down 22084.1 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$115.38M (+43.4%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$46.16M+24.7% QoQ
- Last fiscal yearDec 2025
- -$203.77M+43.2% YoY
- LTMMar 2026
- -$191.86M+46.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.5% | +1.5% | -18.0 pp |
| 1 year | +43.2% | +43.4% | +0.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (203.77M) USD
- Year-over-year change
- +43.2%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (203.77M) | +43.2% |
| FY2024 | 2024-12-31 | (358.76M) | -45.2% |
| FY2023 | 2023-12-31 | (247.01M) | -32.0% |
| FY2022 | 2022-12-31 | (187.06M) | +12.9% |
| FY2021 | 2021-12-31 | (214.78M) | — |
Operating Income vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +46.8% is the 4th highest of 10, against a peer median of -1.9%.
- Operating income amounts to 618909.7% of revenue for LYEL, versus a peer median of 1749.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$28.38M USD | +53.6% | — | — | |
GNLXGenelux Corporation | LTM Mar 2026 | -$33.76M USD | -7.5% | — | 422037.5% |
| LTM Mar 2026 | -$37.36M USD | +60.7% | — | 17.4% | |
| LTM Mar 2026 | -CHF 64.75M CHF | -25.3% | — | 1749.0% | |
| LTM Mar 2026 | -$86.59M USD | — | — | 9396.6% | |
| LTM Mar 2026 | -$115.11M USD | +55.8% | — | 297.5% | |
| LTM Mar 2026 | -$163.79M USD | -1.9% | — | — | |
| LTM Mar 2026 | -$172.43M USD | -63.7% | — | — | |
| LTM Mar 2026 | -$179.4M USD | -33.6% | — | — | |
| LTM Mar 2026 | -$190.22M USD | +29.3% | — | — | |
| LTM Mar 2026 | -$191.86M USD | +46.8% | — | 618909.7% | |
| Peer median (excluding LYEL) | — | -1.9% | — | 1749.0% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| Weighted Avg Shares | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
| Weighted Avg Shares (Diluted) | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.